Indraprastha Medical Corporation financials

·Pharma & HealthChart ›
Latest results Q2 FY27 · Jul–Sep 2026
Revenue
₹413cr+8.4% on Q2 FY26
Net profit
₹53.6cr+8.3% on Q2 FY26
EBITDA margin
18.8%0.0 pts on Q2 FY26
EPS
₹5.84+8.1% on Q2 FY26

Quarterly results

Every quarter ›
₹ croreQ2 FY27Q2 FY26Change
Revenue413381+8.4%
EBITDA77.471.3+8.6%
EBITDA margin18.8%18.7%0.0 pts
Profit before tax72.166.3+8.7%
Net profit53.649.5+8.3%
EPS₹5.84₹5.40+8.1%

Over time

Q2 FY27 · Jul–Sep 2026latest
Revenue₹413 crNet profit₹53.6 crNet margin13.0%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
2,875————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1494.961.561.652.3
2,726————
1,5551,4831,3561,2451,099
—+9.3%+9.0%+13.3%—
280267244193151
18.0%18.0%18.0%15.5%13.7%
233223200153111
19218416112486.2
12.4%12.4%11.9%10.0%7.8%
₹20.96₹20.03₹17.56₹13.52₹9.40
—+14.1%+29.9%+43.9%—
—167157200144
—−59.7−36.3−69.4−44.6
10810812013199.9
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

INDRAMEDCO₹313.60

Indraprastha Medical Corporation Limited

· Pharma & Health
₹ CrorePeersARTEMISMEDSHALBYGKSLGPTHEALTHLOTUSEYEDRAGARWQKMCSHILKOVAIMcap ₹2,875 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————2,874.8
- Cash, Equiv & ST Investments52.361.661.54.9148.6
Enterprise Value————2,726.1
Revenue1,098.71,244.71,356.41,482.51,555.4
Growth %, YoY—+13.3+9.0+9.3—
EBITDA150.7193.4244.3266.9279.7
Margin %13.7215.5318.0118.0017.98
EBIT111.4153.3199.9223.3233.1
Net Income86.2124.0161.0183.6192.1
Margin %7.849.9611.8712.3912.35
EPS, Adj (current shares)9.4013.5217.5620.0320.96
Growth %, YoY—+43.9+29.9+14.1—
Cash from Operations144.5200.2156.8167.4—
Capital Expenditures-44.6-69.4-36.3-59.7—
Free Cash Flow99.9130.8120.4107.8107.8
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Indraprastha Medical Corporation financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Indraprastha Medical Corporation (NSE: INDRAMEDCO) had a market capitalisation of ₹2,918 crore at the 29 October 2026 close (₹318.30 a share), a PE ratio of 15.2 on the last four quarters' profit and a price-to-book ratio of 3.58. In FY26 its consolidated net profit was ₹184 crore on revenue of ₹1,483 crore; in Q2 FY27 (July–September 2026) it was ₹53.6 crore, up 8.3% year on year. It had no borrowings on 30 September 2026. Promoters held 51.00% of the shares on 30 September 2026.

Share price used
₹318.30 · 29 October 2026 close
Latest balance sheet
30 September 2026
Shareholding pattern
30 September 2026

Indraprastha Medical Corporation at a glance · consolidated

Market cap
₹2,918 Crat ₹318.30 · 29 Oct close
PE ratio (last 4 quarters)
15.215.9 on FY26 profit
Price to book (PB)
3.58book value ₹88.84 a share
ROE (FY26)
27.5%−2.5 pts vs FY25ROCE 29.9%
Debt to equity
0.00net cash ₹345 Cr
Promoter holding
51.00%unchanged vs 30 Jun 202630 September 2026
Dividend yield
1.26%₹4 a share in 12 months
Net worth
₹814 Cr+23.7% vs 30 Sep 202530 September 2026
Free cash flow (FY26)
₹108 Cr−10.5% vs FY25

Questions

What is the Indraprastha Medical Corporation PE ratio today?

Indraprastha Medical Corporation's PE ratio is 15.2 at the 29 October 2026 close (₹318.30 a share): a market capitalisation of ₹2,918 crore divided by consolidated net profit of ₹192 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹184 crore) it is 15.9.

What is the Indraprastha Medical Corporation PB ratio (price to book value)?

Indraprastha Medical Corporation's price-to-book (PB) ratio is 3.58 at the 29 October 2026 close: a market capitalisation of ₹2,918 crore divided by shareholders' equity (book value) of ₹814 crore on 30 September 2026. That is a book value of ₹88.84 per share against a share price of ₹318.30.

What is the Indraprastha Medical Corporation net worth?

Indraprastha Medical Corporation's net worth — shareholders' equity in its consolidated balance sheet — was ₹814 crore on 30 September 2026, up 23.7% from ₹658 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹2,918 crore at the 29 October 2026 close.

What is the Indraprastha Medical Corporation market cap?

Indraprastha Medical Corporation's market capitalisation was ₹2,918 crore at the 29 October 2026 close: 9.17 crore shares at ₹318.30 each.

Is Indraprastha Medical Corporation debt free?

Yes. Indraprastha Medical Corporation had no borrowings on 30 September 2026 (consolidated balance sheet), and it held ₹345 crore of cash, bank balances and current investments.

What is the Indraprastha Medical Corporation debt to equity ratio?

Indraprastha Medical Corporation's debt-to-equity ratio was 0.00 on 30 September 2026: no borrowings against total equity of ₹814 crore. A year earlier, on 30 September 2025, it was 0.00.

What is the Indraprastha Medical Corporation ROE and ROCE?

In FY26, Indraprastha Medical Corporation's return on equity (ROE) was 27.5% and its return on capital employed (ROCE) was 29.9%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 30.0% and ROCE 32.5%.

What is the Indraprastha Medical Corporation book value per share?

Indraprastha Medical Corporation's book value per share was ₹88.84 on 30 September 2026: shareholders' equity of ₹814 crore divided by the 9.17 crore shares in issue, up 23.7% from ₹71.82 a year earlier. The share price at the 29 October 2026 close was ₹318.30.

What is the Indraprastha Medical Corporation shareholding pattern?

On 30 September 2026, Indraprastha Medical Corporation's shares were held by promoters 51.00%, foreign portfolio investors (FII/FPI) 2.39%, domestic institutions (DII) 1.77% (including mutual funds at 0.91%) and retail and other non-institutional investors 44.84%. Over the year, FII holding was down 0.02 percentage points from 2.41% and DII holding was down 1.74 percentage points from 3.51%.

What is the Indraprastha Medical Corporation EPS?

Indraprastha Medical Corporation's basic earnings per share (EPS) were ₹20.03 in FY26, against ₹17.56 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹20.95.

What is the Indraprastha Medical Corporation dividend yield?

Indraprastha Medical Corporation's dividend yield is 1.26% at the 29 October 2026 close: dividends of ₹4 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹318.30. They were ₹4 on 18 September 2026.

What is the Indraprastha Medical Corporation promoter holding?

Promoters held 51.00% of Indraprastha Medical Corporation on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.

What is the Indraprastha Medical Corporation dividend in 2026 and its record date?

In 2026, Indraprastha Medical Corporation has declared one dividend: ₹4 with record date 18 September 2026.

What is the Indraprastha Medical Corporation free cash flow?

In FY26, Indraprastha Medical Corporation generated ₹167 crore of cash from operations and spent ₹59.7 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹108 crore. In FY25 it was ₹120 crore.

What are the Indraprastha Medical Corporation latest quarterly results?

Indraprastha Medical Corporation's latest results are for Q2 FY27 (July–September 2026), filed on 29 October 2026: consolidated net profit ₹53.6 crore, up 8.3% from ₹49.5 crore in Q2 FY26; revenue from operations ₹413 crore, up 8.4% year on year.

What is the Indraprastha Medical Corporation revenue and profit in FY26?

In FY26 (April 2025–March 2026), Indraprastha Medical Corporation's consolidated net profit was ₹184 crore, up 14.1% from ₹161 crore in FY25, on revenue from operations of ₹1,483 crore (up 9.3%). Over three years, from FY23, net profit was up 113.1%.

When are the Indraprastha Medical Corporation next results?

Indraprastha Medical Corporation has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.

How does the Indraprastha Medical Corporation PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit, Indraprastha Medical Corporation's PE ratio is 15.9, the lowest of the four: Artemis Medicare Services 45.5, Shalby 35.1 and Gujarat Kidney And Super Speciality 87.4, a peer average of 56.0. Each is the company's market capitalisation at that price divided by its FY26 net profit.

How does Indraprastha Medical Corporation compare with its peers?

On FY26 consolidated figures, against Artemis Medicare Services, Shalby and Gujarat Kidney And Super Speciality: Indraprastha Medical Corporation's operating margin of 15.1% is the second highest of the four (Artemis Medicare Services 13.0%, Shalby 6.4%, Gujarat Kidney And Super Speciality 27.1%; peer average 15.5%); its return on equity of 27.5% is the highest of the four (Artemis Medicare Services 11.7%, Shalby 3.7%, Gujarat Kidney And Super Speciality 6.1%; peer average 7.2%).

Indraprastha Medical Corporation vs Artemis Medicare Services: how do they compare?

In FY26, Indraprastha Medical Corporation earned net profit of ₹184 crore on revenue of ₹1,483 crore, against ₹104 crore on ₹1,081 crore for Artemis Medicare Services. Indraprastha Medical Corporation's operating margin was 15.1% (Artemis Medicare Services 13.0%) and its return on equity 27.5% (Artemis Medicare Services 11.7%). At the 29 October 2026 close, Indraprastha Medical Corporation's market capitalisation was ₹2,918 crore against ₹4,717 crore for Artemis Medicare Services, and its PE ratio on FY26 profit 15.9 against 45.5.

Where do these Indraprastha Medical Corporation figures come from?

From Indraprastha Medical Corporation's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.